Exeantide in Type 2 Diabetes on Insulin

NCT01154933 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication exenatide, when added to insulin therapy, helps manage type 2 diabetes in adults.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 24 people

Who can join Ages 20–75 · all sexes

Timeline Started 2008-04 · est. completion 2011-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01154933 ↗

Description as written by the study sponsor.

Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better glycemic control and weight loss. The purpose of this study is to determine if the addition of Exenatide to diabetic patients will reduce the requirements of insulin particularly the short acting insulin. Exenatide may also lead to decreased inflammation by virtue of better glycemic control and weight loss, or an independent effect.

Treatments tested

exenatide 5 mcg Drug

exenatide 5 mcg
exenatide 10 mcg Drug

exenatide 10 mcg
placebo Drug

saline sq

Main thing measured	Fasting Insulin
Sponsor	University at Buffalo
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01154933 ↗